Arrowstreet Capital
NUVB icon

Arrowstreet Capital’s Nuvation Bio NUVB Stock Holding History

Arrowstreet Capital’s Portfolio NUVB Stock Details NUVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$6.17M Buy
1,439,357
+619,725
+76% +$3.45M ﹤0.01% 1098
2025
Q4 		$7.34M Buy
819,632
+355,636
+77% +$2.2M ﹤0.01% 1027
2025
Q3 		$1.72M Buy
+463,996
New +$1.26M ﹤0.01% 1477
2024
Q2 		– Sell
-38,254
Closed -$139K – 1699
2024
Q1 		$139K Buy
+38,254
New +$73.5K ﹤0.01% 1600

Other funds holding NUVB

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
DFO
Duquesne Family Office New York $3.38B AUM 61.92% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Arrowstreet Capital's NUVB Position: Q1 2026 in Review

Arrowstreet Capital increased its Nuvation Bio (NUVB) stake by 76% in Q1 2026, buying an estimated $3.45M and bringing the position to 1,439,357 shares worth $6.17M. The position accounts for ﹤0.01% of the portfolio, ranked #1098.

Arrowstreet Capital first reported a position in NUVB in Q1 2024 and has held it in 4 quarters since. The position peaked at $7.34M in Q4 2025. 231 funds tracked by Wall St. Rank hold NUVB as of Q1 2026.

  • Arrowstreet Capital held 1,439,357 shares of Nuvation Bio worth $6.17M as of Q1 2026.
  • Arrowstreet Capital bought 619,725 Nuvation Bio shares in Q1 2026, an estimated $3.45M.
  • Nuvation Bio made up ﹤0.01% of Arrowstreet Capital's portfolio in Q1 2026, its #1098 holding.
  • Arrowstreet Capital first reported a position in Nuvation Bio in Q1 2024 and has held it in 4 quarters since.
  • Arrowstreet Capital's Nuvation Bio position peaked at $7.34M in Q4 2025.
  • 231 funds tracked by Wall St. Rank held Nuvation Bio as of Q1 2026.

Based on Arrowstreet Capital's 13F filing for Q1 2026, filed 14 May 2026.